Emergent Biosolutions Inc. (NYSE:EBS) saw unusually-high trading volume on Wednesday . Approximately 823,569 shares traded hands during mid-day trading, an increase of 64% from the previous session’s volume of 500,893 shares.The stock last traded at $28.59 and had previously closed at $28.00.

EBS has been the subject of several research reports. Cowen and Company downgraded Emergent Biosolutions from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 22nd. JPMorgan Chase & Co. reduced their price objective on Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating for the company in a research note on Friday, August 5th. Singular Research reduced their price objective on Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, June 28th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Wednesday, June 22nd. Finally, Zacks Investment Research downgraded Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Tuesday, June 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Emergent Biosolutions presently has a consensus rating of “Buy” and a consensus target price of $40.00.

The firm has a market cap of $1.16 billion, a P/E ratio of 20.45 and a beta of 1.24. The stock has a 50-day moving average of $27.72 and a 200-day moving average of $34.37.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/emergent-biosolutions-inc-ebs-sees-large-volume-increase.html

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. The business had revenue of $101.49 million for the quarter, compared to analyst estimates of $111.20 million. Emergent Biosolutions had a net margin of 11.61% and a return on equity of 11.93%. The firm’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.36 earnings per share. On average, equities analysts forecast that Emergent Biosolutions Inc. will post $1.03 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the stock. Raymond James & Associates increased its stake in shares of Emergent Biosolutions by 0.4% in the second quarter. Raymond James & Associates now owns 8,456 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 36 shares in the last quarter. New York State Teachers Retirement System increased its stake in shares of Emergent Biosolutions by 0.3% in the second quarter. New York State Teachers Retirement System now owns 36,755 shares of the biopharmaceutical company’s stock valued at $1,034,000 after buying an additional 100 shares in the last quarter. Hancock Holding Co. increased its stake in shares of Emergent Biosolutions by 0.5% in the second quarter. Hancock Holding Co. now owns 24,130 shares of the biopharmaceutical company’s stock valued at $679,000 after buying an additional 130 shares in the last quarter. Howe & Rusling Inc. increased its stake in shares of Emergent Biosolutions by 3.0% in the second quarter. Howe & Rusling Inc. now owns 4,875 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 140 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its stake in shares of Emergent Biosolutions by 1.5% in the second quarter. Louisiana State Employees Retirement System now owns 13,800 shares of the biopharmaceutical company’s stock valued at $388,000 after buying an additional 200 shares in the last quarter. Institutional investors own 89.95% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

5 Day Chart for NYSE:EBS

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.